These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 29392440)

  • 21. The cannabinoid system and visual processing: a review on experimental findings and clinical presumptions.
    Schwitzer T; Schwan R; Angioi-Duprez K; Ingster-Moati I; Lalanne L; Giersch A; Laprevote V
    Eur Neuropsychopharmacol; 2015 Jan; 25(1):100-12. PubMed ID: 25482685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases.
    Lowe H; Toyang N; Steele B; Bryant J; Ngwa W
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cannabinoids and atherosclerosis.
    Fisar Z
    Prague Med Rep; 2009; 110(1):5-12. PubMed ID: 19591373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cellular approaches to the interaction between cannabinoid receptor ligands and nicotinic acetylcholine receptors.
    Oz M; Al Kury L; Keun-Hang SY; Mahgoub M; Galadari S
    Eur J Pharmacol; 2014 May; 731():100-5. PubMed ID: 24642359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The potential of cannabinoids and inhibitors of endocannabinoid degradation in respiratory diseases.
    Kicman A; Pędzińska-Betiuk A; Kozłowska H
    Eur J Pharmacol; 2021 Nov; 911():174560. PubMed ID: 34648805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of cannabinoid system on immune modulation: therapeutic implications on CNS inflammation.
    Correa F; Mestre L; Molina-Holgado E; Arévalo-Martín A; Docagne F; Romero E; Molina-Holgado F; Borrell J; Guaza C
    Mini Rev Med Chem; 2005 Jul; 5(7):671-5. PubMed ID: 16026313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Role of endogenous cannabinoids in cerebral reward mechanisms].
    Wenger T; Fürst S
    Neuropsychopharmacol Hung; 2004 Mar; 6(1):26-9. PubMed ID: 15125311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allodynia Lowering Induced by Cannabinoids and Endocannabinoids (ALICE).
    Luongo L; Starowicz K; Maione S; Di Marzo V
    Pharmacol Res; 2017 May; 119():272-277. PubMed ID: 28237514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions.
    Zádor F; Nagy-Grócz G; Kekesi G; Dvorácskó S; Szűcs E; Tömböly C; Horvath G; Benyhe S; Vécsei L
    Molecules; 2019 Oct; 24(20):. PubMed ID: 31619006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glial cells in schizophrenia: a unified hypothesis.
    Dietz AG; Goldman SA; Nedergaard M
    Lancet Psychiatry; 2020 Mar; 7(3):272-281. PubMed ID: 31704113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators.
    Brown I; Cascio MG; Rotondo D; Pertwee RG; Heys SD; Wahle KW
    Prog Lipid Res; 2013 Jan; 52(1):80-109. PubMed ID: 23103355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology.
    Ligresti A; De Petrocellis L; Di Marzo V
    Physiol Rev; 2016 Oct; 96(4):1593-659. PubMed ID: 27630175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychiatric Disorders and Cannabinoid Receptors.
    Joshi N; Onaivi ES
    Adv Exp Med Biol; 2021; 1264():131-153. PubMed ID: 33332008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Enteric Glia and Its Modulation by the Endocannabinoid System, a New Target for Cannabinoid-Based Nutraceuticals?
    López-Gómez L; Szymaszkiewicz A; Zielińska M; Abalo R
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The endocannabinoid system: physiology and pharmacology.
    Rodríguez de Fonseca F; Del Arco I; Bermudez-Silva FJ; Bilbao A; Cippitelli A; Navarro M
    Alcohol Alcohol; 2005; 40(1):2-14. PubMed ID: 15550444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the endocannabinoid system: future therapeutic strategies.
    Aizpurua-Olaizola O; Elezgarai I; Rico-Barrio I; Zarandona I; Etxebarria N; Usobiaga A
    Drug Discov Today; 2017 Jan; 22(1):105-110. PubMed ID: 27554802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cannabinoids and the gut: new developments and emerging concepts.
    Izzo AA; Sharkey KA
    Pharmacol Ther; 2010 Apr; 126(1):21-38. PubMed ID: 20117132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The endocannabinoid system: a revolving plate in neuro-immune interaction in health and disease.
    Tanasescu R; Gran B; Constantinescu CS
    Amino Acids; 2013 Jul; 45(1):95-112. PubMed ID: 22367605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cannabinoids in health and disease: pharmacological potential in metabolic syndrome and neuroinflammation.
    Mastinu A; Premoli M; Ferrari-Toninelli G; Tambaro S; Maccarinelli G; Memo M; Bonini SA
    Horm Mol Biol Clin Investig; 2018 Mar; 36(2):. PubMed ID: 29601300
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.